Recent Developments in Malaria Vaccinology

Advances in Parasitology

Volumn 88, Issue , 2015, Pages 1-49

  Halbroth, Benedict R ^a   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adjuvant; Blood stage; Liver stage; Malaria; Plasmodium; Sporozoite; Transmission blocking; Vaccine

Indexed keywords

CHLOROQUINE; LIVE VACCINE; MALARIA VACCINE; PRIMAQUINE; SPOROZOITE VACCINE; SUBUNIT VACCINE;

ARTICLE; BLOOD; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LIVER; MALARIA; NONHUMAN; PARASITE TRANSMISSION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; RADIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPOROZOITE; VACCINATION; ANIMAL; IMMUNIZATION; IMMUNOLOGY; STANDARDS; TRENDS;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

ANIMALS; HUMANS; IMMUNIZATION; MALARIA; MALARIA VACCINES; SPOROZOITES; VACCINES, SUBUNIT;

EID: 84928210228     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apar.2015.03.001     Document Type: Article

References (270)

1. Abdulla S., Oberholzer R., Juma O., Kubhoja S., Machera F., Membi C., et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 2008, 24:2533-2544.
2. Agnandji S.T., Asante K.P., Lyimo J., Vekemans J., Soulanoudjingar S.S., Owusu R., et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J. Infect. Dis. 2010, 7:1076-1087.
3. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G.N.O., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 2012, 24:2284-2295.
4. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 20:1863-1875.
5. Alger N.E., Harant J. Plasmodium berghei: heat-treated sporozoite vaccination of mice. Exp. Parasitol. 1976, 2:261-268.
6. Alloueche A., Milligan P., Conway D.J., Pinder M., Bojang K., Doherty T., et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am. J. Trop. Med. Hyg. 2003, 1:97-101.
7. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 9443:1411-1420.
8. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 2004, 5:3094-3100.
9. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 9598:1543-1551.
10. Asante K.P., Abdulla S., Agnandji S.T., Lyimo J., Vekemans J., Soulanoudjingar S., et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect. Dis. 2011, 10:741-749.
11. Ballou W.R., Rothbard J., Wirtz R.A., Gordon D.M., Williams J.S., Gore R.W., et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 1985, 4702:996-999.
12. Baum J., Chen L., Healer J., Lopaticki S., Boyle M., Triglia T., et al. Reticulocyte-binding protein homologue 5-an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 2009, 3:371-380.
13. Bauza K., Malinauskas T., Pfander C., Anar B., Jones E.Y., Billker O., et al. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect. Immun. 2014, 3:1277-1286.
14. Behet M.C., Foquet L., van Gemert G., Bijker E.M., Meuleman P., Leroux-Roels G., et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar. J. 2014, 136.
15. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 2008, 24:2521-2532.
16. Bejon P., Mwacharo J., Kai O., Mwangi T., Milligan P., Todryk S., et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 2006, 6:e29.
17. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2007, 8:e707.
18. Belnoue E., Costa F.T.M., Frankenberg T., Vigario A.M., Voza T., Leroy N., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 2004, 4:2487-2495.
19. Bijker E.M., Bastiaens G.J.H., Teirlinck A.C., van Gemert G., Graumans W., van deVegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc. Natl. Acad. Sci. USA 2013, 19:7862-7867.
20. Bijker E.M., Schats R., Obiero J.M., Behet M.C., van Gemert G., van de Vegte-Bolmer M., et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS One 2014, 11:e112910.
21. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic markers associate with Protection against malariain human volunteers immunized with Plasmodium falciparum sporozoites. J.Infect. Dis. 2014, 10:1605-1615.
22. Biswas S., Choudhary P., Elias S.C., Miura K., Milne K.H., de Cassan S.C., et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One 2014, 9:e107903.
23. Biswas S., Dicks M.D.J., Long C.A., Remarque E.J., Siani L., Colloca S., et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 2011, 6:e20977.
24. Biswas S., Spencer A.J., Forbes E.K., Gilbert S.C., Holder A.A., Hill A.V.S., et al. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J. Immunol. 2012, 10:5041-5053.
25. Blagborough A.M., Sinden R.E. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro. Vaccine 2009, 38:5187-5194.
26. Bodescot M., Silvie O., Siau A., Refour P., Pino P., Franetich J., et al. Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol. Res. 2004, 6:449-452.
27. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infectionin semi-immune adult men in the Gambia: a randomised trial. Lancet 2001, 9297:1927-1934.
28. Bojang K.A., Olodude F., Pinder M., Ofori-Anyinam O., Vigneron L., Fitzpatrick S., et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005, 32:4148-4157.
29. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 1990, 6:1633-1641.
30. Brown A.E., Singharaj P., Webster H.K., Pipithkul J., Gordon D.M., Boslego J.W., et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 1994, 2:102-108.
31. Bustamante L.Y., Bartholdson S.J., Crosnier C., Campos M.G., Wanaguru M., Nguon C., et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 2013, 2:373-379.
32. Butler N.S., Schmidt N.W., Harty J.T. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J. Immunol. 2010, 5:2528-2538.
33. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H.I., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 6:451-462.
34. + T cell dynamics in the liver of Plasmodium yoelii immunized and infected mice. PLoS One 2013, 8:e70842.
35. Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier C.S., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010, 2:256-265.
36. Carter R., Graves P.M., Quakyi I.A., Good M.F. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 1989, 1:135-147.
37. de Cassan S.C., Draper S.J. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev. Vaccines 2013, 4:365-378.
38. + T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect. Immun. 2008, 8:3628-3631.
39. Chen H., Xiang Z.Q., Li Y., Kurupati R.K., Jia B., Bian A., et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 2010, 20:10522-10532.
40. Chen L., Lopaticki S., Riglar D.T., Dekiwadia C., Uboldi A.D., Tham W., et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 2011, 9:e1002199.
41. Chen L., Xu Y., Healer J., Thompson J.K., Smith B.J., Lawrence M.C., et al. Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. eLife 2014, 3. 10.7554/eLife.04187.
42. Cheru L., Wu Y., Diouf A., Moretz S.E., Muratova O.V., Song G., et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 2010, 27:4423-4429.
43. Chitnis C.E., Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol. 2008, 1:29-34.
44. Chiu C.Y.H., Healer J., Thompson J.K., Chen L., Kaul A., Savergave L., et al. Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Front. Microbiol. 2014, 314.
45. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013, 2:e55571.
46. Churcher T.S., Bousema T., Walker M., Drakeley C., Schneider P., Ouedraogo A.L., et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. eLife 2013, e00626.
47. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973, 3:169-177.
48. + T cell-mediated elimination of malaria liver stages. Proc. Natl. Acad. Sci. USA 2013, 22:9090-9095.
49. + T cells eliminate liver-stage Plasmodium berghei parasites without detectable bystander effect. Infect. Immun. 2014, 4:1460-1464.
50. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 2010, 1:90-96.
51. Creech C.B., Dekker C.L., Ho D., Phillips S., Mackey S., Murray-Krezan C., et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum. Vaccin. Immunother. 2013, 12:2548-2557.
52. Crosnier C., Bustamante L.Y., Bartholdson S.J., Bei A.K., Theron M., Uchikawa M., et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011, 7378:534-537.
53. Dauby N., Goetghebuer T., Kollmann T.R., Levy J., Marchant A. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect. Dis. 2012, 4:330-340.
54. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., Janse C.J., Mota M.M., et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl. Acad. Sci. USA 2005, 34:12194-12199.
55. Doherty D.G., O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol. Rev. 2000, 5-20.
56. Doherty J.F., Pinder M., Tornieporth N., Carton C., Vigneron L., Milligan P., et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia. Am. J. Trop. Med. Hyg. 1999, 6:865-868.
57. Doll K.L., Harty J.T. Correlates of protective immunity following whole sporozoite vaccination against malaria. Immunol. Res. 2014, 1-3:166-176.
58. + T cells in the Plasmodium yoelii model. J. Immunol. 1999, 2:884-892.
59. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 2000, 3:1453-1462.
60. Douglas A.D., Baldeviano G.C., Lucas C.M., Lugo-Roman L.A., Crosnier C., Bartholdson S.J., et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe 2015, 1:130-139.
61. Douglas A.D., de Cassan S.C., Dicks M.D.J., Gilbert S.C., Hill A.V.S., Draper S.J. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 2010, 44:7167-7178.
62. Douglas A.D., Williams A.R., Illingworth J.J., Kamuyu G., Biswas S., Goodman A.L., et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2011, 601.
63. Douglas A.D., Williams A.R., Knuepfer E., Illingworth J.J., Furze J.M., Crosnier C., et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J. Immunol. 2014, 1:245-258.
64. Drakeley C., Sutherland C., Bousema J.T., Sauerwein R.W., Targett G.A.T. The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol. 2006, 9:424-430.
65. Draper S.J., Biswas S., Spencer A.J., Remarque E.J., Capone S., Naddeo M., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 2010, 12:7583-7595.
66. Draper S.J., Goodman A.L., Biswas S., Forbes E.K., Moore A.C., Gilbert S.C., et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 2009, 1:95-105.
67. Draper S.J., Moore A.C., Goodman A.L., Long C.A., Holder A.A., Gilbert S.C., et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 2008, 8:819-821.
68. Dreyer A.M., Matile H., Papastogiannidis P., Kamber J., Favuzza P., Voss T.S., et al. Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen. J. Immunol. 2012, 12:6225-6237.
69. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27:3501-3504.
70. Duffy P.E., Kaslow D.C. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 1997, 3:1109-1113.
71. Dunachie S.J., Walther M., Epstein J.E., Keating S., Berthoud T., Andrews L., et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 2006, 10:5933-5942.
72. Duncan C.J.A., Draper S.J. Controlled human blood stage malaria infection: current status and potential applications. Am. J. Trop. Med. Hyg. 2012, 4:561-565.
73. Dutta S., Sullivan J.S., Grady K.K., Haynes J.D., Komisar J., Batchelor A.H., et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009, 12:e8138.
74. Edstein M.D., Kotecka B.M., Anderson K.L., Pombo D.J., Kyle D.E., Rieckmann K.H., et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob. Agents Chemother. 2005, 10:4421-4422.
75. El Sahly H.M., Patel S.M., Atmar R.L., Lanford T.A., Dube T., Thompson D., et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin. Vaccine Immunol. 2010, 10:1552-1559.
76. Elias S.C., Choudhary P., de Cassan S.C., Biswas S., Collins K.A., Halstead F.D., et al. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology 2014, 4:628-644.
77. Elias S.C., Collins K.A., Halstead F.D., Choudhary P., Bliss C.M., Ewer K.J., et al. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. J. Immunol. 2013, 3:1135-1147.
78. Epstein J.E., Rao S., Williams F., Freilich D., Luke T., Sedegah M., et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J. Infect. Dis. 2007, 1:145-154.
79. Epstein J.E., Tewari K., Lyke K.E., Sim B.K.L., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8[U+207A] T cell immunity. Science 2011, 6055:475-480.
80. + T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 2013, 2836.
81. Ferreira M.U., Ribeiro W.L., Tonon A.P., Kawamoto F., Rich S.M. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 2003, 65-75.
82. Finney O.C., Keitany G.J., Smithers H., Kaushansky A., Kappe S.H.I., Wang R. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Vaccine 2014, 19:2135-2138.
83. Flanagan K.L., Plebanski M., Akinwunmi P., Lee E.A., Reece W.H., Robson K.J., et al. Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur. J. Immunol. 1999, 6:1943-1954.
84. Foquet L., Hermsen C.C., van Gemert G., van Braeckel E., Weening K.E., Sauerwein R., et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Invest. 2014, 1:140-144.
85. Forbes E.K., de Cassan S.C., Llewellyn D., Biswas S., Goodman A.L., Cottingham M.G., et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. PLoS One 2012, 9:e44943.
86. Friesen J., Silvie O., Putrianti E.D., Hafalla J.C.R., Matuschewski K., Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci. Transl. Med. 2010, 40:40ra49.
87. Garçon N., Chomez P., van Mechelen M. GlaxoSmithKline adjuvant systems invaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007, 5:723-739.
88. Gardner M.J., Doolan D.L., Hedstrom R.C., Wang R., Sedegah M., Gramzinski R.A., et al. DNA vaccines against malaria: immunogenicity and protection in a rodent model. J. Pharm. Sci. 1996, 12:1294-1300.
89. Gbedande K., Varani S., Ibitokou S., Houngbegnon P., Borgella S., Nouatin O., et al. Malaria modifies neonatal and early-life toll-like receptor cytokine responses. Infect. Immun. 2013, 8:2686-2696.
90. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J.Infect. Dis. 2002, 6:820-827.
91. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 1997, 12:1280-1284.
92. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002, 7-8:1039-1045.
93. Good M.F., Engwerda C. Defying malaria: arming T cells to halt malaria. Nat. Med. 2011, 1:49-51.
94. Goodman A.L., Blagborough A.M., Biswas S., Wu Y., Hill A.V.S., Sinden R.E., et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS One 2011, 12:e29428.
95. Goodman A.L., Draper S.J. Blood-stage malaria vaccines - recent progress and future challenges. Ann. Trop. Med. Parasitol. 2010, 3:189-211.
96. Goodman A.L., Epp C., Moss D., Holder A.A., Wilson J.M., Gao G.P., et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 2010, 11:4601-4612.
97. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J.Infect. Dis. 1995, 6:1576-1585.
98. Hayton K., Dumoulin P., Henschen B., Liu A., Papakrivos J., Wellems T.E. Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats. Mol. Biochem. Parasitol. 2013, 2:103-110.
99. Hayton K., Gaur D., Liu A., Takahashi J., Henschen B., Singh S., et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 2008, 1:40-51.
100. Healer J., Thompson J.K., Riglar D.T., Wilson D.W., Chiu Y.C., Miura K., et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. PLoS One 2013, 9:e72504.
101. Hill A.V.S. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 2006, 1:21-32.
102. Hill A.V.S. Vaccines against malaria. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2011, 1579:2806-2814.
103. Hill A.V.S., Biswas S., Draper S., Rampling T., Reyes-Sandoval A. Towards a multi-antigen multi-stage malaria vaccine. Malar. J. 2014, (Suppl. 1), O31.
104. Hodgson S.H., Choudhary P., Elias S.C., Milne K.H., Rampling T.W., Biswas S., et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol. Ther. 2014, 12:2142-2154.
105. Hodgson S.H., Juma E., Salim A., Magiri C., Kimani D., Njenga D., et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front. Microbiol. 2014, 686.
106. Hodgson S.H., Ewer K.J., Bliss C.M., Edwards N.J., Rampling T., Anagnostou N.A., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing CS & ME-TRAP against controlled human malaria infection in malaria naive individuals. J. Infect. Dis. 2015, 7:1076-1086.
107. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., Li T., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 2010, 1:97-106.
108. Hoffman S.L., Doolan D.L. Malaria vaccines-targeting infected hepatocytes. Nat. Med. 2000, 11:1218-1219.
109. Hoffman S.L., Goh L.M.L., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 2002, 8:1155-1164.
110. Holder A.A. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 2009, 12:1445-1456.
111. Hollingdale M.R., Nardin E.H., Tharavanij S., Schwartz A.L., Nussenzweig R.S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 1984, 2:909-913.
112. + T cells drives chronic malaria. Cell. Rep. 2013, 5:1204-1213.
113. Hutchings C.L., Birkett A.J., Moore A.C., Hill A.V.S. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun. 2007, 12:5819-5826.
114. Imai T., Ishida H., Suzue K., Hirai M., Taniguchi T., Okada H., et al. CD8(+) T cell activation by murine erythroblasts infected with malaria parasites. Sci. Rep. 2013, 1572.
115. Jepsen M.P.G., Jogdand P.S., Singh S.K., Esen M., Christiansen M., Issifou S., et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J. Infect. Dis. 2013, 3:479-488.
116. Jin Y., Kebaier C., Vanderberg J. Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect. Immun. 2007, 11:5532-5539.
117. Jones R.M., Chichester J.A., Mett V., Jaje J., Tottey S., Manceva S., et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS One 2013, 11:e79538.
118. Joos C., Marrama L., Polson H.E.J., Corre S., Diatta A., Diouf B., et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 2010, 3:e9871.
119. Kapelski S., Klockenbring T., Fischer R., Barth S., Fendel R. Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J. Leukoc. Biol. 2014, 6:1131-1142.
120. Kappe S.H.I., Vaughan A.M., Boddey J.A., Cowman A.F. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 5980:862-866.
121. Kaslow D.C., Quakyi I.A., Keister D.B. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol. Biochem. Parasitol. 1989, 1:101-103.
122. Kaslow D.C., Quakyi I.A., Syin C., Raum M.G., Keister D.B., Coligan J.E., et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988, 6168:74-76.
123. Kaushansky A., Mikolajczak S.A., Vignali M., Kappe S.H.I. Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections. Cell. Microbiol. 2014, 5:602-611.
124. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 2009, 3:337-346.
125. Khan S.M., Janse C.J., Kappe S.H.I., Mikolajczak S.A. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 2012, 6:908-916.
126. Kimani D., Jagne Y.J., Cox M., Kimani E., Bliss C.M., Gitau E., et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol. Ther. 2014, 11:1992-2003.
127. Kubler-Kielb J., Majadly F., Wu Y., Narum D.L., Guo C., Miller L.H., et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl. Acad. Sci. USA 2007, 1:293-298.
128. Kumar K.A., Sano G., Boscardin S., Nussenzweig R.S., Nussenzweig M.C., Zavala F., et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006, 7121:937-940.
129. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H.I. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 2007, 8:3758-3768.
130. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18:1893-1901.
131. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar. J. 2011, 224.
132. Lell B., Agnandji S.T., von Glasenapp I., Haertle S., Oyakhiromen S., Issifou S., et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS, S malaria vaccine candidates in children in Gabon. PLoS One 2009, 10:e7611.
133. Li C., Mannoor K., Inafuku M., Taniguchi T., Inamine Y., Miyazaki T., et al. Protective function of an unconventional gammadelta T cell subset against malaria infection in apoptosis inhibitor deficient mice. Cell. Immunol. 2012, 2:151-159.
134. Limbach K., Aguiar J.C., Gowda K., Patterson N., Abot E.N., Sedegah M., et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar. J. 2011, 65.
135. Lin J., Annoura T., Sajid M., Chevalley-Maurel S., Ramesar J., Klop O., et al. A novel 'gene insertion/marker out' (GIMO) method for transgene expression and gene complementation in rodent malaria parasites. PLoS One 2011, 12:e29289.
136. Liu M.A. Immunologic basis of vaccine vectors. Immunity 2010, 4:504-515.
137. Llewellyn D., de Cassan S.C., Williams A.R., Douglas A.D., Forbes E.K., Adame-Gallegos J.R., et al. Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome. J. Leukoc. Biol. 2014, 2:369-382.
138. Lyon J.A., Angov E., Fay M.P., Sullivan J.S., Girourd A.S., Robinson S.J., et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 2008, 7:e2830.
139. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 24:3131-3138.
140. March S., Ng S., Velmurugan S., Galstian A., Shan J., Logan D.J., et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 2013, 1:104-115.
141. McCarthy J.S., Marjason J., Elliott S., Fahey P., Bang G., Malkin E., et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One 2011, 9:e24413.
142. McConkey S.J., Reece W.H.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003, 6:729-735.
143. Medica D.L., Sinnis P. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect. Immun. 2005, 7:4363-4369.
144. Mettens P., Dubois P.M., Demoitie M., Bayat B., Donner M., Bourguignon P., et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen. Vaccine 2008, 8:1072-1082.
145. Mikolajczak S.A., Lakshmanan V., Fishbaugher M., Camargo N., Harupa A., Kaushansky A., et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol. Ther. 2014, 9:1707-1715.
146. Miura K., Deng B., Tullo G., Diouf A., Moretz S.E., Locke E., et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS One 2013, 3:e57909.
147. Miura K., Takashima E., Deng B., Tullo G., Diouf A., Moretz S.E., et al. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Infect. Immun. 2013, 12:4377-4382.
148. Miura K., Zhou H., Diouf A., Moretz S.E., Fay M.P., Miller L.H., et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 2009, 7:963-968.
149. Moorthy V., Hill A.V.S. Malaria vaccines. Br. Med. Bull. 2002, 59-72.
150. Moorthy V., Reed Z., Smith P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007, 28:5115-5123.
151. Moorthy V.S., Ballou W.R. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 2009, 312.
152. Moorthy V.S., McConkey S., Roberts M., Gothard P., Arulanantham N., Degano P., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003, 17-18:1995-2002.
153. Moorthy V.S., Newman R.D., Duclos P., Okwo-Bele J.M., Smith P.G. Assessment of the RTS,S/AS01 malaria vaccine. Lancet Infect. Dis. 2013, 4:280-282.
154. Moorthy V.S., Newman R.D., Okwo-Bele J. Malaria vaccine technology roadmap. Lancet 2013, 9906:1700-1701.
155. Moorthy V.S., Reed Z., Smith P.G. MALVAC 2008: measures of efficacy of malaria vaccines in phase 2b and phase 3 trials-scientific, regulatory and public health perspectives. Vaccine 2009, 5:624-628.
156. Mueller A., Labaied M., Kappe S.H.I., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 7022:164-167.
157. Murray C.J., Ortblad K.F., Guinovart C., Lim S.S., Wolock T.M., Roberts D.A., et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 9947:1005-1070.
158. Nahrendorf W., Scholzen A., Bijker E.M., Teirlinck A.C., Bastiaens G.J.H., Schats R., et al. Memory b-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J. Infect. Dis. 2014, 12:1981-1990.
159. Nébié I., Edwards N.J., Tiono A.B., Ewer K.J., Sanou G.S., Soulama I., et al. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin. Vaccine Immunol. 2014, 6:901-903.
160. Niederwieser I., Felger I., Beck H.P. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am. J. Trop. Med. Hyg. 2001, 1-2:9-11.
161. Nikolaeva D., Draper S.J., Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev. Vaccines 2015, 1-28.
162. Nussenzweig R.S., Vanderberg J.P., Most H., Orton C.G. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 5111:160-162.
163. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 2004, 2:351-357.
164. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 1998, 6:1664-1673.
165. Ogwang C., Afolabi M.O., Kimani D., Jagne Y.J., Sheehy S.H., Bliss C.M., et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 2013, 3:e57726.
166. O'Hara G.A., Duncan C.J.A., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 2012, 5:772-781.
167. Olotu A., Lusingu J., Leach A., Lievens M., Vekemans J., Msham S., et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 2011, 2:102-109.
168. Ophorst O.J.A.E., Radosevic K., Havenga M.J.E., Pau M.G., Holterman L., Berkhout B., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect. Immun. 2006, 1:313-320.
169. Osier F.H., Feng G., Boyle M.J., Langer C., Zhou J., Richards J.S., et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014, 108.
170. Osier F.H., Mackinnon M.J., Crosnier C., Fegan G., Kamuyu G., Wanaguru M., et al. New antigens for a multicomponent blood-stage malaria vaccine. Sci. Transl. Med. 2014, 247:247ra102.
171. Ouedraogo A., Tiono A.B., Kargougou D., Yaro J.B., Ouedraogo E., Kabore Y., et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One 2013, 11:e78679.
172. Padte N.N., Boente-Carrera M., Andrews C.D., McManus J., Grasperge B.F., Gettie A., et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One 2013, 10:e78407.
173. Palacpac N.M.Q., Arisue N., Tougan T., Ishii K.J., Horii T. Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine 2011, 35:5837-5845.
174. Pandey A.K., Reddy K.S., Sahar T., Gupta S., Singh H., Reddy E.J., et al. Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies. Infect. Immun. 2013, 2:441-451.
175. Pfeil J., Sepp K.J., Heiss K., Meister M., Mueller A., Borrmann S. Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis. Vaccine 2014, 45:6005-6011.
176. Pinzon-Charry A., McPhun V., Kienzle V., Hirunpetcharat C., Engwerda C., McCarthy J., et al. Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J. Clin. Invest. 2010, 8:2967-2978.
177. Ploemen I.H.J., Croes H.J., van Gemert G.J., Wijers-Rouw M., Hermsen C.C., Sauerwein R.W. Plasmodium berghei Deltap52&p36 parasites develop independent of a parasitophorous vacuole membrane in Huh-7 liver cells. PLoS One 2012, 12:e50772.
178. Polhemus M.E., Remich S.A., Ogutu B.R., Waitumbi J.N., Otieno L., Apollo S., et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 2009, 7:e6465.
179. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 9333:610-617.
180. Raj D.K., Nixon C.P., Nixon C.E., Dvorin J.D., DiPetrillo C.G., Pond-Tor S., et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science 2014, 6186:871-877.
181. Rampling T.W., Bowyer G., Wright D., Edwards N.J., Bliss C.M., Payne R.O., et al. Safety, Immunogenicity and Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-mva Vectored Vaccines Expressing ME-TRAP 2014, The American Society of Tropical Medicine and Hygiene (ASTMH), New Orleans, November 2-6, 2014.
182. Reddy K.S., Amlabu E., Pandey A.K., Mitra P., Chauhan V.S., Gaur D. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc. Natl. Acad. Sci. USA 2015, 4:1179-1184.
183. Reddy K.S., Pandey A.K., Singh H., Sahar T., Emmanuel A., Chitnis C.E., et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect. Immun. 2014, 1:152-164.
184. Remarque E.J., Faber B.W., Kocken C.H.M., Thomas A.W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008, 2:74-84.
185. Rener J., Graves P.M., Carter R., Williams J.L., Burkot T.R. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J. Exp. Med. 1983, 3:976-981.
186. + T-cell responses. Infect. Immun. 2010, 1:145-153.
187. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 2008, 3:732-741.
188. Richie T.L., Charoenvit Y., Wang R., Epstein J.E., Hedstrom R.C., Kumar S., et al. Clinical trial in healthy malaria-naive adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum. Vaccin. Immunother. 2012, 11:1564-1584.
189. Rieckmann K.H., Beaudoin R.L., Cassells J.S., Sell K.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. World Health Organ. 1979, 261-265.
190. Robson K.J., Hall J.R., Jennings M.W., Harris T.J., Marsh K., Newbold C.I., et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 1988, 6185:79-82.
191. + T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol. 2000, 3:157-160.
192. Rodrigues M.M., Cordey A.S., Arreaza G., Corradin G., Romero P., Maryanski J.L., et al. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 1991, 6:579-585.
193. Rodriguez A., Mintardjo R., Tax D., Gillissen G., Custers J., Pau M.G., et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 2009, 44:6226-6233.
194. Roestenberg M., Bijker E.M., Sim B.K.L., Billingsley P.F., James E.R., Bastiaens G.J.H., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 2013, 1:5-13.
195. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J.F., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 2009, 5:468-477.
196. Roestenberg M., Teirlinck A.C., McCall M.B.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 9779:1770-1776.
197. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 6240:323-326.
198. Ross A., Killeen G., Smith T. Relationships between host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 2006, (Suppl. 2), 32-37.
199. Rossignol P.A., Ribeiro J.M., Spielman A. Increased intradermal probing time in sporozoite-infected mosquitoes. Am. J. Trop. Med. Hyg. 1984, 1:17-20.
200. Rutgers T., Gordon D., Gathoye A.M., Hollingdale M., Hockmeyer W., Rosenberg M., et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of plasmodium falciparum. Nat. Biotechnol. 1988, 9:1065-1070.
201. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 2009, 3:329-336.
202. Sack B.K., Miller J.L., Vaughan A.M., Douglass A., Kaushansky A., Mikolajczak S., et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect. Immun. 2014, 2:808-817.
203. Sagara I., Dicko A., Ellis R.D., Fay M.P., Diawara S.I., Assadou M.H., et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009, 23:3090-3098.
204. Sauerwein R.W., Bijker E.M., Richie T.L. Empowering malaria vaccination by drug administration. Curr. Opin. Immunol. 2010, 3:367-373.
205. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 2011, 1:57-64.
206. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 2010, 7:e1000998.
207. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4:397-402.
208. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 6149:664-666.
209. +T cells targeting AMA1 class I epitopes. PLoS One 2014, 9:e106241.
210. Sedegah M., Tamminga C., McGrath S., House B., Ganeshan H., Lejano J., et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 2011, 10:e24586.
211. Seder R.A., Chang L., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 6152:1359-1365.
212. Sheehy S.H., Duncan C.J.A., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 2011, 12:2269-2276.
213. Sheehy S.H., Duncan C.J.A., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012, 2:e31208.
214. Sheehy S.H., Duncan C.J.A., Elias S.C., Choudhary P., Biswas S., Halstead F.D., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 2012, 12:2355-2368.
215. Sheehy S.H., Douglas A.D., Draper S.J. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum. Vaccin. Immunother. 2013, 9:1831-1840.
216. Sheehy S.H., Spencer A.J., Douglas A.D., Sim B.K.L., Longley R.J., Edwards N.J., et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 2013, 6:e65960.
217. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 2014, 3:471-480.
218. Sherwood J.A., Copeland R.S., Taylor K.A., Abok K., Oloo A.J., Were J.B., et al. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 1996, 8:817-827.
219. Shimp R.L.J., Rowe C., Reiter K., Chen B., Nguyen V., Aebig J., et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 2013, 28:2954-2962.
220. Shott J.P., McGrath S.M., Pau M.G., Custers J.H.V., Ophorst O., Demoitie M., et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008, 23:2818-2823.
221. Silvie O., Franetich J., Charrin S., Mueller M.S., Siau A., Bodescot M., et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 2004, 10:9490-9496.
222. Sinden R.E., Blagborough A.M., Churcher T., Ramakrishnan C., Biswas S., Delves M.J. The design and interpretation of laboratory assays measuring mosquito transmission of Plasmodium. Trends Parasitol. 2012, 11:457-465.
223. Sinden R.E., Carter R., Drakeley C., Leroy D. The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies. Malar. J. 2012, 70.
224. Singh A.P., Buscaglia C.A., Wang Q., Levay A., Nussenzweig D.R., Walker J.R., et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 2007, 3:492-504.
225. Sinigaglia F., Guttinger M., Kilgus J., Doran D.M., Matile H., Etlinger H., et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988, 6201:778-780.
226. + T cell responses to malaria antigen ME-TRAP by fusion to MHC class II invariant chain. PLoS One 2014, 6:e100538.
227. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 43:4975-4983.
228. Spring M.D., Cummings J.F., Ockenhouse C.F., Dutta S., Reidler R., Angov E., et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 2009, 4:e5254.
229. Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 2008, 8:3822-3833.
230. Srinivasan P., Ekanem E., Diouf A., Tonkin M.L., Miura K., Boulanger M.J., et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc. Natl. Acad. Sci. USA 2014, 28:10311-10316.
231. Stewart M.J., Nawrot R.J., Schulman S., Vanderberg J.P. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect. Immun. 1986, 3:859-864.
232. Stewart V.A., McGrath S.M., Walsh D.S., Davis S., Hess A.S., Ware L.A., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006, 42-43:6483-6492.
233. Stewart V.A., Walsh D.S., McGrath S.M., Kester K.E., Cummings J.F., Voss G., et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS, S in rhesus macaques. Vaccine 2006, 42-43:6493-6502.
234. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 1997, 2:86-91.
235. Stubbs J., Simpson K.M., Triglia T., Plouffe D., Tonkin C.J., Duraisingh M.T., et al. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 2005, 5739:1384-1387.
236. Sultan A.A., Thathy V., Frevert U., Robson K.J., Crisanti A., Nussenzweig V., et al. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell 1997, 3:511-522.
237. Takala S.L., Coulibaly D., Thera M.A., Batchelor A.H., Cummings M.P., Escalante A.A., et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 2009, 2:2ra5.
238. Tamminga C., Sedegah M., Maiolatesi S., Fedders C., Reyes S., Reyes A., et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin. Immunother. 2013, 10:2165-2177.
239. Tamminga C., Sedegah M., Regis D., Chuang I., Epstein J.E., Spring M., et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011, 10:e25868.
240. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., Camargo N., et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci. USA 2008, 1:305-310.
241. Teirlinck A.C., Roestenberg M., van de Vegte-Bolmer M., Scholzen A., Heinrichs M.J.L., Siebelink-Stoter R., et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J. Infect. Dis. 2013, 4:656-660.
242. A research agenda for malaria eradication: vaccines. PLoS Med. 2011, 1:e1000398. The malERA Consultative Group on Vaccines.
243. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014, 7:e1001685. The RTS, S Clinical Trials Partnership.
244. Theisen M., Roeffen W., Singh S.K., Andersen G., Amoah L., van de Vegte-Bolmer M., et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014, 22:2623-2630.
245. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Ouattara A., Kone A.K., et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 2011, 11:1004-1013.
246. Tran T.M., Ongoiba A., Coursen J., Crosnier C., Diouf A., Huang C., et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J. Infect. Dis. 2014, 5:789-798.
247. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 1998, 12:772-782.
248. VanBuskirk K.M., O'Neill M.T., de la Vega P., Maier A.G., Krzych U., Williams J., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl. Acad. Sci. USA 2009, 31:13004-13009.
249. Vanloubbeeck Y., Pichyangkul S., Bayat B., Yongvanitchit K., Bennett J.W., Sattabongkot J., et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine 2013, 52:6216-6224.
250. Vaughan A.M., Kappe S.H.I., Ploss A., Mikolajczak S.A. Development of humanized mouse models to study human malaria parasite infection. Future Microbiol. 2012, 5:657-665.
251. Vaughan A.M., Mikolajczak S.A., Wilson E.M., Grompe M., Kaushansky A., Camargo N., et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Invest. 2012, 10:3618-3628.
252. Vermeulen A.N., Ponnudurai T., Beckers P.J., Verhave J.P., Smits M.A., Meuwissen J.H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 1985, 5:1460-1476.
253. Vermeulen A.N., van Deursen J., Brakenhoff R.H., Lensen T.H., Ponnudurai T., Meuwissen J.H. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures. Mol. Biochem. Parasitol. 1986, 2:155-163.
254. Villasis E., Lopez-Perez M., Torres K., Gamboa D., Neyra V., Bendezu J., et al. Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. Malar. J. 2012, 361.
255. Volkman S.K., Sabeti P.C., DeCaprio D., Neafsey D.E., Schaffner S.F., Milner D.A., et al. A genome-wide map of diversity in Plasmodium falciparum. Nat. Genet. 2007, 1:113-119.
256. Walther M., Woodruff J., Edele F., Jeffries D., Tongren J.E., King E., et al. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J. Immunol. 2006, 8:5736-5745.
257. Wanaguru M., Liu W., Hahn B.H., Rayner J.C., Wright G.J. RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 2013, 51:20735-20740.
258. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 2001, 19:10817-10822.
259. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 2005, 13:4836-4841.
260. + T lymphocytes in primates immunized with malaria sporozoites. PLoS One 2012, 2:e31247.
261. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. USA 1988, 2:573-576.
262. Wijayalath W., Majji S., Villasante E.F., Brumeanu T.D., Richie T.L., Casares S. Humanized HLA-DR4.RagKO.IL2RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar. J. 2014, 1:386.
263. Williams A.R., Douglas A.D., Miura K., Illingworth J.J., Choudhary P., Murungi L.M., et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 2012, 11:e1002991.
264. Williamson K.C., Kaslow D.C. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230. Mol. Biochem. Parasitol. 1993, 1:125-127.
265. Wright K.E., Hjerrild K.A., Bartlett J., Douglas A.D., Jin J., Brown R.E., et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 2014, 7527:427-430.
266. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 7:e2636.
267. Wu Y., Przysiecki C., Flanagan E., Bello-Irizarry S.N., Ionescu R., Muratova O., et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl. Acad. Sci. USA 2006, 48:18243-18248.
268. Yadava A., Hall C.E., Sullivan J.S., Nace D., Williams T., Collins W.E., et al. Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region. PLoS Negl. Trop. Dis. 2014, 10:e3268.
269. Yoshida N., Nussenzweig R.S., Potocnjak P., Nussenzweig V., Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980, 4426:71-73.
270. Young J.F., Hockmeyer W.T., Gross M., Ballou W.R., Wirtz R.A., Trosper J.H., et al. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science 1985, 4702:958-962.